Next Article in Journal
Routine Screening for Central and Primary Adrenal Insufficiency during Immune-Checkpoint Inhibitor Therapy: An Endocrinology Perspective for Oncologists
Next Article in Special Issue
Triple-Negative Breast Cancer: A Review of Current Curative Intent Therapies
Previous Article in Journal
Gynecologic Cancer Risk and Genetics: Informing an Ideal Model of Gynecologic Cancer Prevention
Previous Article in Special Issue
A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-1401O versus Reference Trastuzumab
 
 
Review

Locoregional Management of Breast Cancer: A Chronological Review

1
Dalhousie University School of Medicine, Dalhousie University, Halifax, NS B3H 1V7, Canada
2
Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada
3
Division of Radiation Oncology, Tom Baker Cancer Centre, 1331 29 St. NW, Calgary, AB T2N 4N2, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2022, 29(7), 4647-4664; https://doi.org/10.3390/curroncol29070369
Received: 22 May 2022 / Revised: 27 June 2022 / Accepted: 29 June 2022 / Published: 1 July 2022
(This article belongs to the Special Issue Evolving Paradigm of Curative Intent Breast Cancer Management)
Locoregional management of breast cancer is founded on evidence generated over a vast time period, much longer than the career span of many practicing physicians. Oncologists rely on specific patient and tumour characteristics to recommend modern-day treatments. However, some of this information may not have been available during prior periods in which the evidence was generated. For example, the comprehensive Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) meta-analyses published in the 2000s typically included older trials accruing patients between the 1960s and 1980s. This raises some uncertainty about whether conclusions from studies conducted in prior eras are as relevant or applicable to modern-day patients and treatments. Reviewing the chronological order and details of the evidence can be beneficial to understanding these nuances. This review discusses the evolution of locoregional management through some key clinical trials. We aim to highlight the time period in which the evidence was generated and emphasize the 10-year outcomes for the comparability of results. Evidence supporting surgical management of the breast and axilla, as well as details of radiotherapy are discussed briefly for all stages of breast cancer. View Full-Text
Keywords: breast cancer; locoregional; management; axilla; surgery; radiotherapy breast cancer; locoregional; management; axilla; surgery; radiotherapy
Show Figures

Figure 1

MDPI and ACS Style

Al-Rashdan, A.; Deban, M.; Quan, M.L.; Cao, J.Q. Locoregional Management of Breast Cancer: A Chronological Review. Curr. Oncol. 2022, 29, 4647-4664. https://doi.org/10.3390/curroncol29070369

AMA Style

Al-Rashdan A, Deban M, Quan ML, Cao JQ. Locoregional Management of Breast Cancer: A Chronological Review. Current Oncology. 2022; 29(7):4647-4664. https://doi.org/10.3390/curroncol29070369

Chicago/Turabian Style

Al-Rashdan, Abdulla, Melina Deban, May Lynn Quan, and Jeffrey Q. Cao. 2022. "Locoregional Management of Breast Cancer: A Chronological Review" Current Oncology 29, no. 7: 4647-4664. https://doi.org/10.3390/curroncol29070369

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop